3.連結財務諸表及び主な注記

(1)連結貸借対照表

 

 

(単位:千円)

 

前連結会計年度

(2024年3月31日)

当連結会計年度

(2025年3月31日)

資産の部

 

 

流動資産

 

 

現金及び預金

296,585

154,663

受取手形及び売掛金

243,290

233,472

商品及び製品

726,359

751,925

仕掛品

22,137

原材料及び貯蔵品

60,868

57,355

預け金

30

179,083

未収入金

1,932

587

その他

37,474

144,014

貸倒引当金

370

2,980

流動資産合計

1,366,170

1,540,257

固定資産

 

 

有形固定資産

 

 

建物及び構築物

33,407

278,833

減価償却累計額

22,588

96,011

建物及び構築物(純額)

10,818

182,821

機械装置及び運搬具

21,931

260,130

減価償却累計額

21,931

130,241

機械装置及び運搬具(純額)

0

129,888

工具、器具及び備品

169,701

213,551

減価償却累計額

155,233

176,473

工具、器具及び備品(純額)

14,467

37,078

土地

551,097

建設仮勘定

178,508

524,032

有形固定資産合計

203,794

1,424,918

無形固定資産

 

 

のれん

70,734

241,056

ソフトウエア

1,872

6,209

その他

283

161

無形固定資産合計

72,891

247,428

投資その他の資産

 

 

長期未収入金

134,419

132,741

敷金及び保証金

34,188

36,499

その他

612

16,334

貸倒引当金

134,419

145,891

投資その他の資産合計

34,800

39,684

固定資産合計

311,486

1,712,030

資産合計

1,677,657

3,252,288

 

 

 

 

(単位:千円)

 

前連結会計年度

(2024年3月31日)

当連結会計年度

(2025年3月31日)

負債の部

 

 

流動負債

 

 

支払手形及び買掛金

268,923

182,128

短期借入金

95,000

1年内返済予定の長期借入金

17,450

未払金

108,870

118,451

未払法人税等

11,770

6,958

契約負債

13,277

5,880

賞与引当金

18,332

17,180

資産除去債務

16,348

その他

34,723

74,095

流動負債合計

455,897

533,493

固定負債

 

 

長期借入金

180,942

繰延税金負債

5,243

12,823

資産除去債務

15,580

10,389

その他

300

39,762

固定負債合計

21,123

243,917

負債合計

477,021

777,410

純資産の部

 

 

株主資本

 

 

資本金

1,134,606

1,851,763

資本剰余金

2,090,726

2,912,688

利益剰余金

2,031,404

2,308,176

株主資本合計

1,193,928

2,456,275

新株予約権

6,707

18,601

純資産合計

1,200,635

2,474,877

負債純資産合計

1,677,657

3,252,288

 

E0567438400パス株式会社PATH corporation通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse384002023-04-012024-03-31jppfs_cor:ShareholdersEquityMember384002023-04-012024-03-31jppfs_cor:SubscriptionRightsToSharesMember384002024-03-31jppfs_cor:CapitalStockMember384002024-03-31jppfs_cor:CapitalSurplusMember384002024-03-31jppfs_cor:RetainedEarningsMember384002024-03-31jppfs_cor:ShareholdersEquityMember384002023-03-31jppfs_cor:CapitalStockMember384002023-03-31jppfs_cor:CapitalSurplusMember384002023-03-31jppfs_cor:RetainedEarningsMember384002023-03-31jppfs_cor:ShareholdersEquityMember384002023-03-31jppfs_cor:SubscriptionRightsToSharesMember384002023-04-012024-03-31jppfs_cor:RetainedEarningsMember384002024-04-012025-03-31jppfs_cor:ShareholdersEquityMember384002024-03-31jppfs_cor:SubscriptionRightsToSharesMember384002025-03-31jppfs_cor:ShareholdersEquityMember384002025-03-31jppfs_cor:CapitalStockMember384002025-03-31jppfs_cor:CapitalSurplusMember384002025-03-31jppfs_cor:RetainedEarningsMember384002025-03-31jppfs_cor:SubscriptionRightsToSharesMember384002024-04-012025-03-31jppfs_cor:CapitalStockMember384002024-04-012025-03-31jppfs_cor:CapitalSurplusMember384002024-04-012025-03-31jppfs_cor:RetainedEarningsMember384002024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember384002023-04-012024-03-31jppfs_cor:CapitalStockMember384002023-04-012024-03-31jppfs_cor:CapitalSurplusMember384002025-05-13384002025-03-31384002024-04-012025-03-31384002024-03-31384002023-04-012024-03-31384002023-03-31384002024-04-012025-03-31tse-acedjpfr-38400:CosmeticsBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:BeautyAndWellnessBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:MarketExpansionBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:InvestmentBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:CosmeticsBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:BeautyAndWellnessBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:MarketExpansionBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:InvestmentBusinessReportableSegmentsMember384002024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember384002023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:RegenerativeMedicineRelatedBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:SustainableBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:RegenerativeMedicineRelatedBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:SustainableBusinessReportableSegmentsMember384002024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember384002023-04-012024-03-31jpcrp_cor:ReconcilingItemsMember384002024-04-012025-03-31tse-acedjpfr-38400:AITechnologyReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:AITechnologyReportableSegmentsMemberxbrli:pureiso4217:JPY